• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从东到西:日本制药公司建立全球研究能力的视角。

From East to West: a Japanese Pharma perspective on establishing a global research capability.

机构信息

Global Research Management, Pharmaceutical Research Department, Takeda Pharmaceutical Company, Yodogawa-Ku, Osaka, Japan.

出版信息

Drug Discov Today. 2009 Jun;14(11-12):611-7. doi: 10.1016/j.drudis.2009.03.010. Epub 2009 Mar 31.

DOI:10.1016/j.drudis.2009.03.010
PMID:19508924
Abstract

Takeda (http://www.takeda.com) is one of the oldest Pharmaceutical companies in the world and has been the largest Japanese Pharmaceutical company for over a decade. Although many of its operations such as development and marketing have been conducted on a global basis for a number of years, research has historically been focused on in-house activities inside Japan, which have a successful track record in generating pioneer blockbuster drugs. To meet the ever-increasing challenge of maintaining a robust pipeline and a continuous stream of INDs, Takeda has embarked on a program to globalize its internal drug discovery capability through the integration of world-class research entities. We outline the strategies, opportunities and challenges of building a global research network from the perspective of a Japanese Pharmaceutical company.

摘要

武田制药(http://www.takeda.com)是世界上最古老的制药公司之一,也是十年来日本最大的制药公司。尽管其研发和营销等多项业务多年来一直是在全球范围内进行的,但历史上的研究一直集中在日本国内的内部活动上,这些活动在开发先驱重磅药物方面有着成功的记录。为了应对不断增加的挑战,保持强大的产品线和源源不断的 IND,武田制药通过整合世界级的研究实体,启动了一项计划,旨在使内部药物发现能力全球化。我们从日本制药公司的角度概述了建立全球研究网络的战略、机遇和挑战。

相似文献

1
From East to West: a Japanese Pharma perspective on establishing a global research capability.从东到西:日本制药公司建立全球研究能力的视角。
Drug Discov Today. 2009 Jun;14(11-12):611-7. doi: 10.1016/j.drudis.2009.03.010. Epub 2009 Mar 31.
2
Drug discovery alliances.药物研发联盟。
Nat Rev Drug Discov. 2005 Oct;4(10):807-8. doi: 10.1038/nrd1856.
3
Open innovation: the new face of pharmaceutical research and development.开放式创新:药物研发的新面貌。
Expert Rev Clin Pharmacol. 2012 Sep;5(5):481-3. doi: 10.1586/ecp.12.44.
4
Antibacterial drug discovery: is small pharma the solution?抗菌药物研发:小型制药公司是解决之道吗?
Clin Microbiol Infect. 2004 Nov;10 Suppl 4:32-6. doi: 10.1111/j.1465-0691.2004.1008.x.
5
Tuberculosis vaccines: a strategic blueprint for the next decade.结核病疫苗:未来十年的战略蓝图。
Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S6-13. doi: 10.1016/S1472-9792(12)70005-7.
6
Opportunities and challenges in the discovery of new central nervous system drugs.新型中枢神经系统药物研发中的机遇与挑战
Ann N Y Acad Sci. 2008 Nov;1144:243-50. doi: 10.1196/annals.1418.024.
7
Brazil: An emerging partner in drug R&D.巴西:药物研发领域的新兴合作伙伴。
IDrugs. 2009 Aug;12(8):497-502.
8
Looking forward in pharmaceutical process chemistry.展望药物过程化学。
Science. 2009 Aug 7;325(5941):701-4. doi: 10.1126/science.1174501.
9
[Malaria research for developing countries: the PAL+ program].[面向发展中国家的疟疾研究:PAL+项目]
Med Trop (Mars). 2003;63(3):236-40.
10
Digital pathology in drug discovery and development: multisite integration.药物发现与开发中的数字病理学:多站点整合
Drug Discov Today. 2009 Oct;14(19-20):935-41. doi: 10.1016/j.drudis.2009.06.013. Epub 2009 Jul 9.